The Survey Research Center (SRC) was founded in April 1991 and has been a Cancer Center Shared Resource since 2003. Its purpose is to facilitate the conduct of high quality science through the provision of excellent consultation and service delivery for all aspects of survey design and conduct for Mayo Clinic Cancer Center (MCCC) investigators. Under the leadership of Dr. Timothy Beebe (since 2004), the SRC strives for excellence by providing high quality and efficient service delivery by deploying "state of the science" methods in the areas of instrument development, sampling, mailing, telephoning, response tracking, instrument processing, and data file preparation. The SRC is the only Mayo Clinic facility offering this comprehensive set of services. The SRC has conducted over 2,000 survey-based studies since its inception. Over the course of the past grant period (2008-2013), the SRC has consulted on -192 separate survey projects. Of these, 45 were led by MCCC investigators representing a wide range of programs (n = 10) with Women's Cancer, Cancer Control and Prevention (CPC), Genetic Epidemiology and Risk Assessment (GERA), and Hematologic Malignancies being among the most frequent users. Overall, ~ 60% of MCCC investigators using SRC services did so with funding supplied by peer-reviewed and competitive extramural grant support. For MCCC investigators, this resource has and will continue to provide expert consultation and support for the conduct of survey research relevant to their research endeavors. The initial consultations and assistance with proposal development, overall research design, and questionnaire design are done at no charge to MCCC members due to the support provided by the CCSG. For all other services (questionnaire formatting, web survey programming, editorial review, printing, mailings, telephoning, updating the tracking system, data entry, data analysis, and reporting) MCCC investigators are given priority access to SRC services and resources. MCCC investigators are given priority access to SRC services and resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682939
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$61,495
Indirect Cost
$22,861
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications